To assess the effectiveness of immune checkpoint blockade (ICB) in HCC patients at high and low risk, we utilized the TIDE algorithm, an innovative approach that integrates G6PD expression levels and HBV infection factors (Figure 8B). The gene discussed is G6PD; the disease is hepatocellular carcinoma.